Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
AA

Ratings ESG MSCI

Ratings Sanofi: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company has a good ESG score relative to its sector, according to MSCI.
Highlights: Sanofi
  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The company's attractive earnings multiples are brought to light by a P/E ratio at 12.25 for the current year.
  • With regards to fundamentals, the enterprise value to sales ratio is at 2.17 for the current period. Therefore, the company is undervalued.
  • The company has a low valuation given the cash flows generated by its activity.
  • This company will be of major interest to investors in search of a high dividend stock.
  • Sales forecast by analysts have been recently revised upwards.
Weaknesses: Sanofi
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
  • Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The company's earnings releases usually do not meet expectations.

Rating Financials

Sanofi SectorFrance

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Sanofi SectorFrance

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Sanofi SectorFrance

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Sanofi SectorFrance

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Sanofi SectorFrance

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
107B
AA
1,031B
A
641B -
BBB
- -
453B
AA
-
349B
AA
290B
AAA
252B
A
232B
A
201B
A
181B
AA
Average 373.66B
AA
Weighted average by Cap.
AA